Health
Bristol Myers Gets US Nod for First New Schizophrenia Drug Type in Decades
- Millions of patients may benefit from new treatment approach
- Product puts Bristol ‘on the map’ beyond cancer therapies
This article is for subscribers only.
Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
The medication, to be sold under the name Cobenfy, gained Food and Drug Administration clearance Thursday to treat the illness that often produces hallucinations and delusions.